Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.
Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
The CEO's experience launching medical reference app Epocrates led him to found a social network for physicians.
Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste
The federal government alleged that the drugmaker instructed its sales reps to convey messages to doctors that downplayed the drug's safety risks.
Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
The goal is to further cement point of care as a mainstream media channel.
One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
If scientific storytelling alone can impact health outcomes, then how can we apply that knowledge in practice?
The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations
Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season
Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise
Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
With physicians spending nearly four hours a day on their electronic health records, experts say voice assistants could help reduce their workload one day.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
The deal highlights ongoing interest in the influential point-of-care market.
Fitness trackers do not reliably track calories, docs find; health-tech startups face market uncertainty; FDA adcom votes in favor of Puma breast-cancer drug
Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.
In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.
Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs